.

• • The BIO protocol rose from $0.05 to $0.07, reaching the upper limit of its monthly trading range ($0.054 - $0.073)

• • Despite the rise, BIO remains 90% lower than its all-time high of $0.81

• • The market capitalization is now around $130 million with highly volatile trading volumes

Main drivers

• • The imminent listing on the Pointpay Exchange platform on August 8 is believed to be driving the expected positions

• • The reason for the Coinbase listing on August 1 caused a price drop of 7.3% before the recent recovery

• • The cryptocurrency sectors of DeSci and biotechnology continue to face challenges of financing and regulatory ambiguity

• • Recent regulatory clarifications by the Securities and Exchange Commission (SEC) regarding liquid staking may indirectly affect cryptocurrencies specialized in biotechnology

Trading considerations

• • Technical resistance at the $0.073 level is significant - breaking it could aim for $0.085, while failure indicates a return to $0.06

• • The timing of the rise coincided with the platform's listing driver rather than substantive improvements in the project

• • High volatility requires the use of tight stop-loss orders and conservative position sizing

• • Strategies vary: it is an entry point for risk-tolerant investors or an opportunity to exit for those seeking to reduce exposure

Market sentiment

• • The user community anticipated this movement, with previous discussions identifying the oversold condition of BIO

• • The currency avoided concerns about the Coinbase listing, providing stability despite the challenges facing the sector

• • The continuation of this rise depends on the volume after the listing and whether BIO can form support above the $0.07 level